Hypertension Severity and Declines in Left Ventricular Ejection Fraction Among Women Receiving Adjuvant Chemotherapy for Breast Cancer (WF-97415 UPBEAT).
Article in Hypertension (Dallas, Tex. : 1979), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Improving Exercise Capacity With a Tailored Physical Activity Intervention in Lymphoma and Breast Cancer Patients Undergoing Treatment - An Addendum to NIH R01CA167821 "Early Imaging Detection of Cardiovascular Injury After Cancer"
TypeinterventionalSponsorWake Forest University Health SciencesRan2013 to 2022Enrolled28ConditionsCardiac Toxicity, Malignant Neoplasm, Breast CancerArmsMagnetic resonance imaging, Physical Activity, Healthy Living, Cardiopulmonary Exercise Testing (CPET), Questionnaire Administration
NCT02791581 naactive not recruitingnot on this map
Understanding and Predicting Breast Cancer Events After Treatment (UPBEAT)
TypeinterventionalSponsorWake Forest University Health SciencesRan2017 to 2034Enrolled403ConditionsBreast CancerArmsCardiac MRI
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors at 3 institutions in 1 country.
Riya GargDivision of Cardiology, VCU Health Pauley Heart Center (R.G., F.N.S., J.H.J., W.B., K.C.O., A.C.L., W.G.H.), Virginia Commonwealth University (VCU), Richmond.
Ralph B D'AgostinoDepartment of Biostatistics and Data Science (R.B.D., N.C.), Wake Forest School of Medicine, Winston-Salem, NC.ORCID 0000-0002-3550-8395
Nathaniel O'ConnellDepartment of Biostatistics and Data Science (R.B.D., N.C.), Wake Forest School of Medicine, Winston-Salem, NC.ORCID 0000-0002-3827-5152
Glenn J LesserSection on Hematology and Oncology, Department of Internal Medicine (G.J.L.), Wake Forest School of Medicine, Winston-Salem, NC.
Fadi N SalloumDivision of Cardiology, VCU Health Pauley Heart Center (R.G., F.N.S., J.H.J., W.B., K.C.O., A.C.L., W.G.H.), Virginia Commonwealth University (VCU), Richmond.
Anika L HinesDepartment of Health Behavior and Policy (A.L.H.), Virginia Commonwealth University (VCU), Richmond.ORCID 0000-0003-3502-5606
Giselle C MeléndezSection on Cardiovascular Medicine, Department of Internal Medicine (G.C.M.), Wake Forest School of Medicine, Winston-Salem, NC.
Jennifer H JordanDivision of Cardiology, VCU Health Pauley Heart Center (R.G., F.N.S., J.H.J., W.B., K.C.O., A.C.L., W.G.H.), Virginia Commonwealth University (VCU), Richmond.ORCID 0000-0003-1001-1849
Bonnie KyDepartment of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (B.K.).ORCID 0000-0002-6628-9981
Lynne I WagnerDivision of Public Health Sciences, Department of Social Sciences and Health Policy (L.I.W.), Wake Forest School of Medicine, Winston-Salem, NC.ORCID 0000-0001-9685-4796
Arnethea L SuttonDepartment of Kinesiology and Health Sciences (A.L.S.), Virginia Commonwealth University (VCU), Richmond.ORCID 0000-0002-4398-0278
Wendy BottinorDivision of Cardiology, VCU Health Pauley Heart Center (R.G., F.N.S., J.H.J., W.B., K.C.O., A.C.L., W.G.H.), Virginia Commonwealth University (VCU), Richmond.ORCID 0000-0002-6743-5776
Kristine C OlsonDivision of Cardiology, VCU Health Pauley Heart Center (R.G., F.N.S., J.H.J., W.B., K.C.O., A.C.L., W.G.H.), Virginia Commonwealth University (VCU), Richmond.ORCID 0000-0002-2952-3003
Amy C LaddDivision of Cardiology, VCU Health Pauley Heart Center (R.G., F.N.S., J.H.J., W.B., K.C.O., A.C.L., W.G.H.), Virginia Commonwealth University (VCU), Richmond.
William Gregory HundleyDivision of Cardiology, VCU Health Pauley Heart Center (R.G., F.N.S., J.H.J., W.B., K.C.O., A.C.L., W.G.H.), Virginia Commonwealth University (VCU), Richmond.ORCID 0000-0002-2433-8853
UPBEAT Study Team
Virginia Commonwealth University · USWake Forest University · USUniversity of Pennsylvania · US
Funding
ECOG-ACRIN NCORP Research Base - TMISTUG1CA189828 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$199.7M
Wake Forest NCORP Research BaseUG1CA189824 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Emily Van Meter Dressler, GLENN J LESSER · 2014 to 2026
$57.9M
Understanding and Predicting Fatigue, CV Decline & Events After Breast CA TreatmentR01CA199167 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI HUNDLEY, WILLIAM GREGORY · 2015 to 2022
$3.2M
Early Imaging Detection of CV Injury after CancerR01CA167821 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI HUNDLEY, WILLIAM GREGORY, JOLLY, MARIE-PIERRE · 2012 to 2016
backgroundHypertension is a risk factor for experiencing left ventricular ejection fraction (LVEF) declines during receipt of potentially cardiotoxic breast cancer (BC) treatment. We sought to determine whether the hypertension stage is associated with LVEF decline during BC treatment.
methodsAcross 24 centers, cardiac magnetic resonance measures of LVEF and brachial arterial blood pressure (BP) measurements were performed in women with stages I to III BC before and 3 months after initiating potentially cardiotoxic chemotherapy. Using multivariable analysis, we assessed in a blinded fashion the association between 3-month ΔLVEF and precancer treatment American Heart Association/American College of Cardiology stages of hypertension.
resultsAmong 204 women, age averaged 56±1 years with 75% being White and 20% of Black race. Participants received anthracycline (45.6%), trastuzumab (22.5%), cyclophosphamide (52.9%), or paclitaxel (50%). After accounting for pretreatment LVEF, diabetes status, tobacco use, age, the number of antihypertensive medications, and body mass index, those with stage II hypertension experienced an LVEF decline of -2.89% ([95% CI, -0.69% to -5.19%];
conclusionsCompared with women receiving treatment for BC with normal BP, there is a stronger association of decline in LVEF in women with stage II hypertension relative to women with other hypertension stages. This raises the possibility that stage along with hypertension presence may be associated with an increased risk for the LVEF decline among women receiving potentially cardiotoxic chemotherapy for BC. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02791581 and NCT01719562.
Indexed as
Breast NeoplasmsHypertensionStroke VolumeChemotherapy, AdjuvantCyclophosphamideFemaleHumansMiddle AgedSeverity of Illness IndexVentricular Dysfunction, LeftVentricular Function, LeftCyclophosphamideblood pressurecardiovascular diseasesheart failurehypertensionrisk factors
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Hypertension Severity and Declines in Left Ventricular Ejection Fraction Among Women Receiving Adjuvant Chemotherapy for Breast Cancer (WF-97415 UPBEAT). · full record | OpenQuestion